Toward a Future Where Diabetes No Longer Limits Mesh Surgery

Area of Science:

• Urogynecology
• Biomaterials Science
• Endocrinology

Background:

• Synthetic mesh use in urogynecologic surgery has advanced, yet patient-specific factors like diabetes are linked to mesh complications.
• Diabetes is prevalent in women undergoing pelvic floor surgery, increasing the risk of adverse outcomes.
• Current management often overlooks the impact of glycemic control on mesh implantation success.

Purpose of the Study:

• To review perioperative glucose management strategies in surgical patients.
• To discuss the relevance of glucose control to synthetic mesh implantation in urogynecologic surgery.
• To highlight the need for individualized patient management and further research.

Main Methods:

• Literature review of perioperative glucose management in surgical populations.
• Analysis of the impact of diabetes and glycemic variability on mesh outcomes.
• Discussion of current assessment markers (e.g., HbA1c) and their limitations.

Main Results:

• Preoperative HbA1c is insufficient for predicting mesh outcomes.
• Intra- and postoperative glucose control significantly affects surgical results, but optimal targets are undefined.
• Glycemic variability and hyperglycemia impair immune function and tissue quality, complicating patient management.

Conclusions:

• A precision medicine approach integrating patient-specific factors is needed for urogynecologic mesh surgery.
• Further research into mechanistic pathways, biomarkers, and computational modeling is essential.
• Individualized diabetes management strategies are critical for improving long-term mesh implant success.